Vertex Pharmaceuticals Incorporated
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 5.4K
- Market Cap
- $123.9B
- Website
- http://www.vrtx.com
Clinical Trials
639
Active:400
Completed:178
Trial Phases
5 Phases
Phase 1:397
Phase 2:65
Phase 3:85
+2 more phases
Drug Approvals
4
FDA:4
Clinical Trials
Distribution across different clinical trial phases (558 trials with phase data)• Click on a phase to view related trials
Phase 1
397 (71.1%)Phase 3
85 (15.2%)Phase 2
65 (11.6%)Phase 4
5 (0.9%)phase_1_2
3 (0.5%)Not Applicable
2 (0.4%)phase_2_3
1 (0.2%)Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants
Not Applicable
Not yet recruiting
- Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Interventions
- First Posted Date
- 2025-07-20
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 148
- Registration Number
- NCT07074327
A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants
Phase 1
Recruiting
- Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-06-15
- Last Posted Date
- 2025-07-15
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 24
- Registration Number
- NCT07022119
- Locations
- 🇺🇸
ICON Lenexa, Lenexa, Kansas, United States
A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations
- First Posted Date
- 2025-06-08
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 136
- Registration Number
- NCT07010406
- Locations
- 🇺🇸
Celerion - Tempe, Tempe, Arizona, United States
🇺🇸Celerion - Lincoln, Lincoln, Nebraska, United States
A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I
- First Posted Date
- 2025-04-14
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 36
- Registration Number
- NCT06926621
- Locations
- 🇬🇧
Leonard Wolfson Experimental Neurology Centre CRF, London, United Kingdom
🇦🇺Wesley Research Institute, Auchenflower, Australia
🇦🇺Neuroscience Clinical Trials Unit, Alfred Brain, Melbourne, Australia
A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries
- First Posted Date
- 2025-03-21
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 100
- Registration Number
- NCT06887972
- Locations
- 🇺🇸
Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸HD Research LLC | First Surgical Hospital, Bellaire, Texas, United States
🇺🇸Memorial Hermann Village, Houston, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 47
- Next
News
No news found